je.st
news
Tag: patients
Essure patients testify in Washington
2014-06-14 02:57:11| Chemicals - Topix.net
Women who say they were harmed by the permanent birth control device, Essure , testified Thursday before a Congressional Briefing in Washington, D.C. Cleveland resident Kim Hudak, 42, told her story to a panel of Congressional aides and officials as part of a Hill Briefing called, "Reforming the FDA: The Impact of Proposed Changes on Patients and ... (more)
Tags: washington
patients
testify
Merck to Present New Clinical Data on JANUVIA (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association
2014-06-06 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA (sitagliptin) and for its investigational once-weekly DPP-4 inhibitor omarigliptin, at the 74th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco, June 13-17, 2014. Several analyses of patient data in real-world settings will also be presented. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orKim Hamilton908-423-6831 or 908-391-0131orInvestor:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
First Presentation of Data for Pembrolizumab, Mercks Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014
2014-06-02 13:30:00| Merck.com - Corporate News
Dateline City: CHICAGO Initial Therapy with Pembrolizumab Demonstrates Robust Anti-Tumor Activity with Tumor Shrinkage in 80 Percent of Evaluable PD-L1 Positive, Advanced NSCLC Patients Merck Initiating Phase 3 Study with Pembrolizumab Versus Platinum-Based Doublet Chemotherapy as First-Line Therapy in PD-L1 Positive, Advanced NSCLC (KEYNOTE-024) Additional 50 Patients Enrolled in KEYNOTE-001 with Analyses Planned Using Mercks Proprietary PD-L1 Assay at One Percent and 50 Percent Cut Points CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data evaluating pembrolizumab (MK-3475), Mercks investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia Contacts:Ian McConnell, (973) 901-5722orClaire Mulhearn, (908) 423-7425orInvestor Contacts:Carol Ferguson, (908) 423-4465orJustin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
cell
presentation
Dutch Cancer Patients to Benefit from Erasmus Medical Center's New Treatment Technology
2014-06-02 06:00:00| Industrial Newsroom - All News for Today
Largest medical center in the Netherlands upgrades with several Elekta Versa HD linear accelerators<br /> <br /> ROTTERDAM, the Netherlands — Clinicians at the Erasmus University Medical Center (Erasmus MC) in Rotterdam, the Netherlands, will be able to offer patients the most modern cancer treatment available through its purchase of Elekta Versa HD™ linear accelerators (linacs) and a substantial software upgrade including Elekta's MOSAIQ® oncology information system and Monaco® 5 ...This story is related to the following:SoftwareSearch for suppliers of: Planning Software |
Tags: technology
medical
treatment
benefit
IMBRUVICA (ibrutinib) Shows Durable, Long-Term Responses for Patients with CLL
2014-06-01 03:48:06| Logistics - Topix.net
Pharmacyclics, Inc. announced today that IMBRUVICA will be featured in an oral presentation highlighting long-term responses to treatment, with up to three years of follow up in 132 patients with treatment naive or relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma .
Tags: shows
patients
responses
durable
Sites : [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] next »